Abstract:Abstract Background Atherosclerosis is a chronic lipid-driven inflammatory disease with infiltration of low-density lipoprotein and is considered as the pivotal step in plaque formation. The aim of the review is to get into the fine details of pathophysiologic mechanisms responsible for atherosclerosis with atherosclerotic lesion classification. It also provides a summary of current biomarkers other than the traditional risk factors so that new treatment modalities can emerge and reduce the morbidity and mortality associated with atherosclerosis. Main body In the classification of atherosclerosis made by American Heart Association (AHA), AHA Type I lesion is the earliest vascular change described microscopically. AHA Type II lesion is primarily composed of abundant macrophages. AHA Type III lesion is the earliest of progressive lesions, while AHA Type IV lesion consists of an acellular necrotic core. Various biomarkers are implicated in different stages of the pathophysiological mechanism of plaque formation and evolution. C Reactive Protein plays a direct role in promoting the inflammatory component of atherosclerosis. Fibrinogen was demonstrated to be elevated among patients with acute thrombosis. Higher leukocyte count is associated with a greater cardiovascular risk. Cytokines have been implicated in atheroma formation and complications. High rates of protease activated receptor expression are also induced by interleukin-6 secretion in atherosclerotic lesions and areas of vascular tissue injury. Cluster of differentiation 40 receptor and its ligand have been also detected in atherosclerotic plaques. Osteopontin, acidic phosphoprotein, and osteoprotegerin have emerged as novel markers of atherosclerotic plaque composition. There are also overproductions of matrix metalloproteinases in the rupture-prone regions and promote lipid-necrotic core formation in the atherosclerotic plaque. Myeloperoxidase has been proposed as a marker of plaque instability. Oxidized low-density lipoprotein receptor 1 provides a route of entry for oxidized low-density lipoprotein into the endothelium. A human atherosclerotic lesion also expresses lipoprotein-associated phospholipase A 2 . Short conclusion Atherosclerotic plaques are the battlefield between an unbalanced immune response and lipid accumulation in the intima of arteries. Most of the biomarkers associated with atherosclerosis are indicators of inflammatory response and will also be used for medical purposes.

Targeting B cells in atherosclerosis: closing the gap from bench to bedside

B Cells in Atherosclerosis: Mechanisms and Potential Clinical Applications

Functional Role of B Cells in Atherosclerosis

Beyond Macrophages and T Cells: B Cells and Immunoglobulins Determine the Fate of the Atherosclerotic Plaque

Atherosclerosis antigens as targets for immunotherapy

B cells and atherosclerosis: A HIV perspective

Antibodies in action: the role of humoral immunity in the fight against atherosclerosis

T Cells in Atherosclerosis: Key Players in the Pathogenesis of Vascular Disease

Atherosclerosis: Beyond the lipid storage hypothesis. The role of autoimmunity

Tipping the Scale: Atheroprotective IgM-Producing B Cells in Atherosclerosis

ApoB-Specific CD4+ T Cells in Mouse and Human Atherosclerosis

Targeting immune cell recruitment in atherosclerosis

Abstract 21: B-1b Cells Secrete Atheroprotective IgM and Attenuate Atherosclerosis

Single-cell profiling of CD11c+ B cells in atherosclerosis

Protective role of natural IgM-producing B1a cells in atherosclerosis

The cellular biology of atherosclerosis with atherosclerotic lesion classification and biomarkers

Targeting B cells and plasma cells in autoimmune diseases: from established treatments to novel therapeutic approaches

The immune system in atherosclerosis

Immunobiology of Atherosclerosis: A Complex Net of Interactions

Atherosclerosis: Insights into Vascular Pathobiology and Outlook to Novel Treatments

Pharmacological therapy targeting the immune response in atherosclerosis